Modern thoracic oncology continuously seeks effective therapeutic options for patients with advanced lung malignancies who progress after initial immunotherapy. Recently published results from a first-in-human clinical study evaluated rilvegostomig for nsclc in checkpoint inhibitor-experienced cohorts. This novel bispecific antibody simultaneously targets programmed cell death protein-1 and T-cell immunoreceptor with immunoglobulin and ITIM domains. Consequently, researchers designed the molecule to overcome acquired treatment resistance mechanisms. This phase I/II study provides critical insights into safety, pharmacokinetics, and preliminary antitumor efficacy.

Dual Target Mechanism of Rilvegostomig for NSCLC

Immune checkpoint monotherapies targeting the programmed cell death-1 pathway have transformed thoracic oncology. However, many patients eventually develop therapeutic resistance and experience disease progression. Consequently, novel co-inhibitory targets such as T-cell immunoreceptor with immunoglobulin and ITIM domains have attracted considerable scientific interest. Rilvegostomig directly addresses this clinical challenge through an engineered monovalent bispecific antibody design. Specifically, the molecule binds simultaneously to both pathways on tumor-infiltrating lymphocytes. This bi-specific engagement enhances receptor occupancy and restores exhausted T-cell activity more effectively than monotherapy. Furthermore, selective co-engagement of dual-positive immune cells optimizes local intratumoral activity while minimizing systemic toxicity risks. As a result, dual pathway blockade offers a rational strategy to re-engage anti-tumor immunity in pretreated non-small-cell lung cancer. Moreover, preclinical models demonstrated that this simultaneous binding anchors the drug to tumor-infiltrating lymphocytes with high affinity. Therefore, dual checkpoint co-inhibition provides a compelling therapeutic mechanism for refractory malignancies.

Phase I/II Study Design and Patient Cohorts

The multicenter, open-label phase I/II trial evaluated intravenous administration of the bispecific antibody in PD-L1-positive advanced non-small-cell lung cancer. Importantly, all enrolled participants had previously received checkpoint inhibitor therapy and demonstrated subsequent disease progression. Part A of the study represented a dose-escalation phase involving fifty-one subjects. These patients received intravenous infusions at escalating dose levels of 70 mg, 210 mg, 750 mg, and 1500 mg once every three weeks. Following dose escalation, Part B enrolled thirty-two patients into an expansion cohort after investigators established the recommended phase II dose. Pharmacodynamic assays, pharmacokinetic profiling, and clinical safety metrics were systematically evaluated across all treatment groups. In addition, baseline clinical characteristics reflected a heavily pretreated population with significant disease burden and limited therapeutic options. Overall, this structured study design allowed rigorous evaluation of safety thresholds while gathering preliminary efficacy signals. Furthermore, the trial included comprehensive biomarker assessments to evaluate target engagement across diverse patient subgroups.

Dose Escalation and RP2D Determination

Establishing an optimal therapeutic dose represents a primary goal during early-phase oncology trials. During Part A dose escalation, investigators observed zero dose-limiting toxicities across all dose levels up to 1500 mg. Furthermore, the maximum tolerated dose was not reached during the escalation phase. Based on integrated pharmacokinetic, pharmacodynamic, and preliminary efficacy data, researchers selected 750 mg once every three weeks as the recommended phase II dose. This selected dose level demonstrated full target engagement without inducing excessive immunologic toxicity. Consequently, the dose expansion cohort in Part B utilized this 750 mg schedule to confirm tolerability and preliminary activity. Establishing a clear recommended dose enables clinicians to maximize therapeutic exposure while protecting patient safety. Therefore, these preliminary pharmacokinetic findings established a reliable dosing foundation for subsequent clinical evaluation arms. Additionally, clear dose selection helps streamline future phase II and phase III clinical protocol development.

Safety and Tolerability Profile in Clinical Settings

Safety evaluations demonstrated a highly favorable toxicity profile for the bispecific construct in this pretreated patient population. At the formal data cut-off date, treatment-emergent adverse events of any grade occurred in 90.4% of patients. However, treatment-related adverse events occurred in 54.2% of subjects, indicating a manageable adverse event profile. Grade 3 treatment-related adverse events were reported in only 8.4% of participants, and no grade 4 or 5 treatment-related events occurred. Additionally, investigator-assessed immune-mediated adverse events were observed in 18.1% of patients. Crucially, treatment discontinuation due to drug-related toxicity occurred in only 2.4% of subjects. Consequently, these findings confirm that simultaneous dual checkpoint inhibition does not cause unexpected cumulative toxicities. Furthermore, the remarkably low discontinuation rate underscores the clinical feasibility of administering this agent to frail patients. Overall, the safety profile compares favorably with historic combination immunotherapy regimens.

Efficacy Metrics in Checkpoint Inhibitor-Experienced Patients

Clinical efficacy remains a critical endpoint when evaluating novel therapies for refractory metastatic non-small-cell lung cancer. Among patients treated at the recommended phase II dose, the objective response rate reached 5.6%. Furthermore, the six-month disease control rate reached 31.5%, indicating meaningful disease stabilization in a portion of refractory cases. Median progression-free survival across the evaluated cohort reached 3.8 months, while the twelve-month progression-free survival rate was 11.9%. Although objective response rates were modest in this heavily pretreated population, the observed disease control indicates durable clinical benefit for select patients. Consequently, these metrics demonstrate that bispecific inhibition can delay disease progression after primary checkpoint inhibitor failure. In addition, ongoing translational analyses aim to identify specific immune biomarkers that predict durable clinical responses. Ultimately, these clinical outcomes offer valuable proof-of-concept for dual-targeting approaches in resistant thoracic tumors.

Future Directions and Implications for Thoracic Oncology

The favorable tolerability profile and encouraging disease control support further clinical development of this dual-checkpoint antibody strategy. Consequently, investigators have expanded the trial into Parts C through E to evaluate broader clinical indications. These ongoing study cohorts assess safety and efficacy in checkpoint inhibitor-naïve patients presenting with nonsquamous or squamous non-small-cell lung cancer with PD-L1 expression levels of at least 1% or 50%. Evaluating the bispecific antibody in earlier treatment settings may generate higher response rates by targeting unexhausted immune cell populations. Furthermore, combining bispecific antibodies with standard platinum-based chemotherapy represents another promising clinical avenue. Ultimately, dual-targeting agents like rilvegostomig could redefine therapeutic strategies for advanced non-small-cell lung cancer across frontline and salvage clinical management.

Frequently Asked Questions

What is rilvegostomig and how does it function in lung cancer?

Rilvegostomig is a novel monovalent bispecific antibody designed to target both PD-1 and TIGIT immune checkpoint pathways simultaneously. By blocking two complementary inhibitory receptors on T cells, the agent enhances anti-tumor immune activation. Furthermore, this bi-specific design achieves selective target engagement within the tumor microenvironment, potentially overcoming resistance to traditional single-agent anti-PD-1 or anti-PD-L1 checkpoint therapies in patients with non-small-cell lung cancer.

What were the primary safety findings of the Phase I/II clinical trial?

The Phase I/II trial demonstrated a favorable safety profile with no dose-limiting toxicities and no maximum tolerated dose reached during escalation. Treatment-related adverse events occurred in 54.2% of patients, with grade 3 events occurring in only 8.4%. Furthermore, immune-mediated adverse events occurred in 18.1% of subjects, while treatment discontinuation due to adverse events was low at 2.4%, confirming excellent overall drug tolerability.

What efficacy outcomes were achieved at the recommended Phase II dose?

At the recommended phase II dose of 750 mg every three weeks, patients achieved an objective response rate of 5.6% and a 6-month disease control rate of 31.5%. Additionally, median progression-free survival was 3.8 months, and 12-month progression-free survival reached 11.9%. These outcomes demonstrate meaningful clinical activity and disease stabilization in patients who previously progressed on prior checkpoint inhibitor therapies.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Rohrberg KS et al. Rilvegostomig for Metastatic Non-Small-Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study. Clin Cancer Res. 2026 Aug 10. doi: 10.1158/1078-0432.CCR-26-0333. PMID: 42574065.


2. ClinicalTrials.gov. A Study of AZD2936 (Rilvegostomig) Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer. Identifier: NCT04995523.


3. Chau I. Next-Generation Immune Checkpoint Inhibitors in Upper Gastrointestinal Cancers: The Role of TIGIT. ASCO Daily News. 2026 Feb 4.